Literature DB >> 16299553

The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.

Cuiyan Xin1, Shuyu Ren, Wolfgang Eberhardt, Josef Pfeilschifter, Andrea Huwiler.   

Abstract

1.--The immunomodulating agent FTY720 is a substrate for the sphingosine kinase and the phosphorylated form is able to bind to sphingosine 1-phosphate (S1P) receptors. In this study, we show that exposure of renal mesangial cells to phospho-FTY720 leads to a rapid and transient activation of several protein kinase cascades, including the mitogen- and stress-activated protein kinases. The nonphosphorylated FTY720 also increased MAPK phosphorylation, but with a reduced potency and a more delayed time course. In addition, phospho-FTY720 and FTY720 are able to increase phosphorylation of Smad proteins which are classical members of the transforming growth factor-beta (TGF-beta) signalling device, thus suggesting a crosstalk between FTY720 and TGF-beta signalling. 2.--Pretreatment with the S1P(3) receptor antagonist suramin inhibits FTY720 and phospho-FTY720-induced Smad phosphorylation, whereas pertussis toxin pretreatment, which blocks G(i/0) proteins, has no effect on Smad phosphorylation. 3.--Since TGF-beta is a potent profibrotic cytokine in mesangial cells and upregulates the connective tissue growth factor (CTGF) and collagen as important hallmarks in the fibrotic sequelae, we investigated whether FTY720 and phospho-FTY720 are able to mimic these effects of TGF-beta. Indeed, FTY720 and phospho-FTY720 markedly upregulate CTGF and collagen type IV protein expressions. In addition, the tissue inhibitor of metalloproteinase-1 is transcriptionally activated by FTY720, whereas cytokine-induced matrix metalloproteinase-9 is down-regulated by FTY720. 4.--Depletion of the TGF-beta receptor type II by the siRNA transfection technique blocks not only Smad phosphorylation but also CTGF upregulation. Similarly, Smad-4 depletion by siRNA transfection also abrogates CTGF upregulation induced by FTY720 and phospho-FTY720. 5.--In summary, our data show that FTY720 and phospho-FTY720 not only activate the Smad signalling cascade in mesangial cells, but also upregulate the expression of CTGF and collagen. These findings suggest that FTY720 may have additional effects besides the established immunomodulatory action and, importantly, a profibrotic activity has to be considered in future experimental approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16299553      PMCID: PMC1615856          DOI: 10.1038/sj.bjp.0706452

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

Review 1.  TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells.

Authors:  Sharon M Wahl; Jennifer Swisher; Nancy McCartney-Francis; Wanjun Chen
Journal:  J Leukoc Biol       Date:  2004-02-13       Impact factor: 4.962

2.  1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate.

Authors:  M Manggau; D S Kim; L Ruwisch; R Vogler; H C Korting; M Schäfer-Korting; B Kleuser
Journal:  J Invest Dermatol       Date:  2001-11       Impact factor: 8.551

3.  Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells.

Authors:  W Eberhardt; T Beeg; K F Beck; S Walpen; S Gauer; H Böhles; J Pfeilschifter
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

4.  Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.

Authors:  Haruhito Azuma; Shiro Takahara; Naotsugu Ichimaru; Jing Ding Wang; Yuko Itoh; Yoshinori Otsuki; Junji Morimoto; Ryosuke Fukui; Masaaki Hoshiga; Tadashi Ishihara; Norio Nonomura; Seiichi Suzuki; Akihiko Okuyama; Yoji Katsuoka
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.

Authors:  Bruce L Riser; Mark Denichilo; Pedro Cortes; Cathryn Baker; Janet M Grondin; Jerry Yee; Robert G Narins
Journal:  J Am Soc Nephrol       Date:  2000-01       Impact factor: 10.121

6.  Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis.

Authors:  F Wang; J R Van Brocklyn; J P Hobson; S Movafagh; Z Zukowska-Grojec; S Milstien; S Spiegel
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

7.  Structural determinants of binding and specificity in transforming growth factor-receptor interactions.

Authors:  P K Shah; C M Buslje; R Sowdhamini
Journal:  Proteins       Date:  2001-12-01

8.  Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells.

Authors:  J Guo; K L MacDonell; W R Giles
Journal:  Pflugers Arch       Date:  1999-10       Impact factor: 3.657

9.  Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells.

Authors:  R Franzen; A Pautz; L Bräutigam; G Geisslinger; J Pfeilschifter; A Huwiler
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

10.  CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720.

Authors:  G Henning; L Ohl; T Junt; P Reiterer; V Brinkmann; H Nakano; W Hohenberger; M Lipp; R Förster
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  19 in total

1.  Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

Authors:  Christina D Keller; Pilar Rivera Gil; Markus Tölle; Markus van der Giet; Jerold Chun; Heinfried H Radeke; Monika Schäfer-Korting; Burkhard Kleuser
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

Authors:  S-K Jo; A Bajwa; A S Awad; K R Lynch; M D Okusa
Journal:  Kidney Int       Date:  2008-03-05       Impact factor: 10.612

3.  TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Authors:  Keith R Stayrook; Justin K Mack; Donna Cerabona; Daniel F Edwards; Hai H Bui; Maria Niewolna; Pierrick Gj Fournier; Khalid S Mohammad; David L Waning; Theresa A Guise
Journal:  Bonekey Rep       Date:  2015-07-08

4.  Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells.

Authors:  Hesham M El-Shewy; Mimi Sohn; Parker Wilson; Mi Hye Lee; Samar M Hammad; Louis M Luttrell; Ayad A Jaffa
Journal:  Mol Endocrinol       Date:  2012-03-15

5.  Sphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination.

Authors:  Caroline A Blanc; Jonathan J Grist; Hugh Rosen; Ilse Sears-Kraxberger; Oswald Steward; Thomas E Lane
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

6.  FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.

Authors:  Haifeng Ni; Junfeng Chen; Mingming Pan; Minghui Zhang; Jiandong Zhang; Pingsheng Chen; Bicheng Liu
Journal:  J Mol Histol       Date:  2013-08-02       Impact factor: 2.611

7.  Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.

Authors:  Katrin Sobel; Katalin Menyhart; Nina Killer; Bérengère Renault; Yasmina Bauer; Rolf Studer; Beat Steiner; Martin H Bolli; Oliver Nayler; John Gatfield
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

Review 8.  Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling.

Authors:  Deborah A Lebman; Sarah Spiegel
Journal:  J Lipid Res       Date:  2008-04-02       Impact factor: 5.922

9.  Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist.

Authors:  Scott E Wenderfer; Stanislaw M Stepkowski; Michael C Braun
Journal:  Kidney Int       Date:  2008-09-03       Impact factor: 10.612

10.  Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.

Authors:  F L Scott; B Clemons; J Brooks; E Brahmachary; R Powell; H Dedman; H G Desale; G A Timony; E Martinborough; H Rosen; E Roberts; M F Boehm; R J Peach
Journal:  Br J Pharmacol       Date:  2016-04-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.